We are focused on developing and marketing safe and effective regenerative and cell-based therapies based on our cellular platforms, to treat serious injury and degenerative diseases including cancers, orthopedic diseases including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases. We have developed proprietary practical knowledge in the use of cell-based therapeutics that we believe could be used to help a great number of people suffering from cancer and serious chronic diseases.
Our technology includes 2 major cell platforms: Stem Cell and Cancer Immune Cell
The unique lines of adult adipose-derived stem cells and the immune cell therapies enable us to create multiple cell formulations in treating specific medical conditions and diseases, as well as applying single cell types in a specific treatment protocol. Our facilities are certified to meet the international standards NSF/ANSI 49, ISO-14644 (or equivalent), ANSI/NCSL Z-540-1 and 10CFR21, as well as Chinese CFDA standards CNAS L0221. In addition to standard protocols, we use proprietary processes and procedures for manufacturing our cell lines, comprised of:
- Banking processes that ensure cell preservation and viability;
- DNA identification for stem cell origin chain of custody; and
- Bio-safety testing at independently certified laboratories.